

AEPCOS QUARTERLY PUBLICATION LIST

JULY—SEPTEMBER 2014

Highlighted articles

Cassina M, Donà M, Di Gianantonio E, Litta P, Clementi M. First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis. Hum Reprod Update. 2014 Sep-Oct;20(5):656-69. doi: 10.1093/humupd/dmu022. Epub 2014 May 25. Review. PMID: 24861556.

Commentary (CM):

The use of metformin during the first trimester of pregnancy is supported by the lack of reports suggesting an increased rate of major birth defects in the offspring of women treated with this drug. However, specific studies addressing this issue have not been published. Metformin is a category-B drug according to the FDA pregnancy classification, meaning that “animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.”

The object of this meta-analysis was to review prospective and retrospective studies on women treated with metformin during the first-trimester of pregnancy to determine the frequency of major birth defects. The inclusion criteria were patients with PCOS or pre-pregnancy diabetes type 2, and first-trimester exposure to metformin. A disease-matched control group not exposed to metformin or other anti-diabetic agents was used for comparison.

In nine controlled studies of PCOS patients that met the criteria for inclusion, it was detected that the rate of major birth defects in the metformin exposed group was statistically similar when compared with the disease-matched control group. The metformin-exposed sample was composed of 351 pregnancies and the OR of major birth defects was 0.86 (95% confidence interval: 0.18–4.08). By evaluating all of the non-overlapping PCOS studies, even those without an appropriate control group, the rate of major anomalies was 0.6% in the sample of 517 women who discontinued the therapy upon conception or confirmation of pregnancy and 0.5% in the sample of 634 women who were treated with metformin during the first trimester of their pregnancy. On the other hand, there were not sufficient studies regarding type 2 diabetic women exposed to metformin during the first trimester to proceed with the meta-analysis.

However, there are several limitations: 1) the data were taken from studies not specifically designed to evaluate the rate of congenital defects; 2) the samples were small, highly selected and non-homogeneous in terms of treatment protocols for infertility, duration of treatment, obesity and glycemic control; 3) no detailed information on other medications taken during pregnancy was reported. The authors concluded that there is currently no evidence that metformin is associated with an increased risk of major birth defects in women affected by PCOS and treated during the first trimester. In addition, they suggest that larger

ad hoc studies are warranted in order to definitely confirm the safety and efficacy of this drug in pregnancy. Nonetheless, to design a study of this type has important ethical implications; although metformin is generally regarded as a non-teratogenic drug, it would be inappropriate to expose a large number of pregnant women to use a drug only to determine their degree of teratogenicity.

Ujvari U, Hulchiy M, Calaby A, Nybacka Å, Byström B, Hirschberg AL. Lifestyle intervention up-regulates gene and protein levels of molecules involved in insulin signaling in the endometrium of overweight/obese women with polycystic ovary syndrome. Hum Reprod. 2014 Jul;29(7):1526-35.

Commentary (KH)

While there is evidence for weight loss in PCOS improving metabolic parameters, there is debate on the possible impact of weight reduction on pregnancy rates. There is some concern that obesity decreases pregnancy rates and implantation rates in IVF including in donor oocyte IVF suggesting there are specific endometrial impacts of obesity. It is also possible that menstrual dysfunction is exacerbated by obesity. Unfortunately there are few data published on the impact of weight loss on the endometrium. The impact of insulin resistance that is associated with PCOS may impact the endometrium adversely. Many studies that demonstrate ovulatory responses to treatment in PCOS do not show correspondingly high pregnancy rates despite this ovulatory response suggesting independent endometrial effect. Lifestyle modification is an important component of the clinical treatment of PCOS in the setting of obesity but its impact on the endometrium has had limited study. The authors of this paper included 20 women who were obese with a history of PCOS (mean BMI of 37 kg/m²) in a lifestyle intervention program for 3 months. This was an individualized weight reduction program involving dietary restriction and increased physical activity. Women had monthly visits with a dietician and followed a high protein diet. They were prescribed aerobic activity for 45 minutes 2-3 times per week and were given gym memberships. At the start of the program and at 3 months they were given endometrial biopsies. The investigators also studied 10 obese controls, 9 normal weight women with PCOS and 10 normal weight control women. Of the 20 women enrolled in the lifestyle intervention program, the investigators were only able to analyse the data in 17 as 2 dropped out of the program and one had insufficient endometrial sampling. Average body weight decreased by 5% and 88% had some weight reduction. Menstrual patterns improved in 65% and 35% were documented to be ovulatory. Proliferative endometrium was studied. Endometrial insulin signalling was studied in the specimens. It was noted that endometrial levels of insulin receptor substrate -1 (IRS1) and glucose transporter 4 (GLUT4) mRNA were significantly lower in obese women with PCOS compared to BMI matched control women suggesting an impact of insulin resistance on the endometrium of PCOS women. After the intervention there was a significant increase in IRS1 and GLUT1, particularly in those who demonstrated improved menstrual

function. This increased level was comparable to those in the normal groups. Overall this suggests that lifestyle intervention enhances the function of IRS1 and insulin sensitivity in the endometrium of obese women with PCOS and it appears to correlate with improved menstrual function. It remains to be seen if these improvements have a role in improvement in fertility or pregnancy rates however.

LIST OF PUBLICATIONS

Congenital Adrenal Hyperplasia and Disorders of Steroidogenesis

Metwalley KA, El-Saied AR. Bone mineral status in Egyptian children with classic congenital adrenal hyperplasia. A single-center study from Upper Egypt. *Indian J Endocrinol Metab.* 2014 Sep;18(5):700-4. doi: 10.4103/2230-8210.139236 PMID: 25285289

Eckoldt-Wolke F. Timing of surgery for feminizing genitoplasty in patients suffering from congenital adrenal hyperplasia. *Endocr Dev.* 2014;27:203-9. doi: 10.1159/000363664. Epub 2014 Sep 9. PMID: 25247657

Guercio G, Rey RA. Fertility issues in the management of patients with disorders of sex development. *Endocr Dev.* 2014;27:87-98. doi: 10.1159/000363633. Epub 2014 Sep 9. PMID: 25247647

Pasterski V, Zucker KJ, Hindmarsh PC, Hughes IA, Acerini C, Spencer D, Neufeld S, Hines M. Increased Cross-Gender Identification Independent of Gender Role Behavior in Girls with Congenital Adrenal Hyperplasia: Results from a Standardized Assessment of 4- to 11-Year-Old Children. *Arch Sex Behav.* 2014 Sep 20. [Epub ahead of print] PMID: 25239661

van der Kaay D, van den Akker E. Ultralow-dose Dexamethasone to Preserve Endogenous Cortisol Stress Response in Nonclassical Congenital Adrenal Hyperplasia: A New Promising Treatment. *Int J Endocrinol Metab.* 2014 Jul 1;12(3):e14657. doi: 10.5812/ijem.14657. eCollection 2014 Jul. PMID: 25237318

Kirac D, Guney AI, Akcay T, Guran T, Ulucan K, Turan S, Ergec D, Koc G, Eren F, Kaspar EC, Bereket A. The Frequency and the Effects of 21-Hydroxylase Gene Defects in Congenital Adrenal Hyperplasia Patients. *Ann Hum Genet.* 2014 Sep 17. doi: 10.1111/ahg.12083. [Epub ahead of print] PMID: 25227725

Doleschall M, Szabó JA, Pázmándi J, Szilágyi Á, Koncz K, Farkas H, Tóth M,

Igaz P, Gláz E, Prohászka Z, Korbonits M, Rácz K, Füst G, Patócs A. Common genetic variants of the human steroid 21-hydroxylase gene (CYP21A2) are related to differences in circulating hormone levels. *PLoS One*. 2014 Sep 11;9(9):e107244. doi: 10.1371/journal.pone.0107244. eCollection 2014. PMID: 25210767

Claahsen-van der Grinten HL, Dehzad F, Kamphuis-van Ulzen K, de Korte CL. Increased prevalence of testicular adrenal rest tumours during adolescence in congenital adrenal hyperplasia. *Horm Res Paediatr*. 2014;82(4):238-44. doi: 10.1159/000365570. Epub 2014 Sep 3. PMID: 25195868

Erdogan G, Pabuccu R, Ertek S, Israel S, Yilmaz B, Yilmaz H, Caglar G. Late-onset congenital adrenal hyperplasia with Cushing syndrome. *Intern Med*. 2014;53(17):1955-9. Epub 2014 Sep 1. PMID: 25175129

Baldinger L, Mudegowdar A, Shukla AR. Abnormalities of the external genitalia. *Clin Perinatol*. 2014 Sep;41(3):709-24. doi: 10.1016/j.clp.2014.05.016. Epub 2014 Jul 23. PMID: 25155737

Bechtold S, Beyerlein A, Bonfig W, Dalla Pozza R, Putzker S, Otto R, Schmidt H, Schwarz HP. Sexual difference in bone geometry of adult patients with classical congenital adrenal hyperplasia: data using peripheral quantitative computed tomography. *Horm Res Paediatr*. 2014;82(3):171-8. doi: 10.1159/000362759. Epub 2014 Aug 22. PMID: 25171196

Gilban DL, Alves Junior PA, Beserra IC. Health related quality of life of children and adolescents with congenital adrenal hyperplasia in Brazil. *Health Qual Life Outcomes*. 2014 Aug 13;12:107. doi: 10.1186/s12955-014-0107-2. PMID: 25115634

Amr NH, Ahmed AY, Ibrahim YA. Carotid intima media thickness and other cardiovascular risk factors in children with congenital adrenal hyperplasia. *J Endocrinol Invest*. 2014 Oct;37(10):1001-8. doi: 10.1007/s40618-014-0148-8. Epub 2014 Aug 12. PMID: 25112902

Ray JA, Kushnir MM, Yost RA, Rockwood AL, Wayne Meikle A. Performance enhancement in the measurement of 5 endogenous steroids by LC-MS/MS combined with differential ion mobility spectrometry. *Clin Chim Acta*. 2015 Jan 1;438:330-6. doi: 10.1016/j.cca.2014.07.036. Epub 2014 Aug 9. PMID: 25110813

Sahmay S, Tuten A, Gurleyen H, Oncul M, Benian A, Tamer Erel C. Diagnosis of late-onset congenital adrenal hyperplasia in clinical practice: current evaluation. *Minerva Endocrinol*. 2014 Sep;39(3):215-22. PMID: 25068307

Krysiak R, Okopien B. The Effect of Metformin on Androgen Production in Diabetic Women with Non-classic Congenital Adrenal Hyperplasia. *Exp Clin Endocrinol Diabetes*. 2014 Nov;122(10):568-71. doi: 10.1055/s-0034-1382048. Epub 2014 Jul 23. PMID: 25054311

Böttcher B, Dörr HG, Wildt L. Naltrexone as a diagnostic tool to distinguish between hyperandrogenemic and hypothalamic ovarian failure in females with congenital adrenal hyperplasia due to 21-hydroxylase-deficiency (CAH). *Eur J Obstet Gynecol Reprod Biol*. 2014 Sep;180:153-6. doi: 10.1016/j.ejogrb.2014.06.007. Epub 2014 Jun 24. PMID: 25065344

Houben CH, Tsui SY, Mou JW, Chan KW, Tam YH, Lee KH. Reconstructive surgery for females with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a review from the Prince of Wales Hospital. *Hong Kong Med J*. 2014 Dec;20(6):481-5. doi: 10.12809/hkmj144227. Epub 2014 Jul 18. PMID: 25045882

Vitkin E, Ben-Dor A, Shmoish M, Hartmann MF, Yakhini Z, Wudy SA, Hochberg Z. Peer group normalization and urine to blood context in steroid metabolomics: the case of CAH and obesity. *Steroids*. 2014 Oct;88:83-9. doi: 10.1016/j.steroids.2014.07.003. Epub 2014 Jul 17. PMID: 25042470

Livadas S, Dracopoulou M, Dastamani A, Sertedaki A, Maniati-Christidi M, Magiakou AM, Kanaka-Gantenbein C, Chrousos GP, Dacou-Voutetakis C. The spectrum of clinical, hormonal and molecular findings in 280 individuals with nonclassical congenital adrenal hyperplasia caused by mutations of the CYP21A2 gene. *Clin Endocrinol (Oxf)*. 2014 Jul 5. doi: 10.1111/cen.12543. [Epub ahead of print] PMID: 25041270

Thyen U, Lux A, Jürgensen M, Hiort O, Köhler B. Utilization of health care services and satisfaction with care in adults affected by disorders of sex development (DSD). *J Gen Intern Med*. 2014 Aug;29 Suppl 3:S752-9. doi: 10.1007/s11606-014-2917-7. PMID: 25029980

Leccese A, Longo V, Dimatteo C, De Girolamo G, Trunzo R, D'Andrea G, Bafunno V, Margaglione M, Santacroce R. Lack of genotype-phenotype correlation in congenital adrenal hyperplasia due to a CYP21A2-like gene. *Clin Chim Acta*. 2014 Nov 1;437:48-51. doi: 10.1016/j.cca.2014.07.009. Epub 2014 Jul 12. PMID: 25025300

Goodarzi MO, Carmina E, Azziz R. DHEA, DHEAS and PCOS. *J Steroid Biochem Mol Biol*. 2014 Jul 5. pii: S0960-0760(14)00117-4. doi: 10.1016/j.jsbmb.2014.06.003. [Epub ahead of print] Review. PMID: 25008465

Delvecchio M, Soldano L, Lonero A, Ventura A, Giordano P, Cavallo L, Grano M, Brunetti G, Faienza MF. Evaluation of impact of steroid replacement treatment on bone health in children with 21-hydroxylase deficiency. *Endocrine*. 2014 Jul 1. [Epub ahead of print] PMID: 24981037

Sharma V, Thangaraj K, Jyothy A. A novel androgen receptor gene mutation in a patient with congenital adrenal hyperplasia associated with penoscrotal hypospadias. *Transl Res*. 2014 Aug;164(2):149-52. doi: 10.1016/j.trsl.2014.03.013. Epub 2014 May 6. PMID: 24907477

Han TS, Conway GS, Willis DS, Krone N, Rees DA, Stimson RH, Arlt W, Walker BR, Ross RJ; United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE). Relationship between final height and health outcomes in adults with congenital adrenal hyperplasia: United Kingdom congenital adrenal hyperplasia adult study executive (CaHASE). *J Clin Endocrinol Metab*. 2014 Aug;99(8):E1547-55. doi: 10.1210/jc.2014-1486. Epub 2014 May 30. PMID: 24878054

Kim MS, Ryabets-Lienhard A, Bali B, Lane CJ, Park AH, Hall S, Geffner ME. Decreased adrenomedullary function in infants with classical congenital adrenal hyperplasia. *J Clin Endocrinol Metab*. 2014 Aug;99(8):E1597-601. doi: 10.1210/jc.2014-1274. Epub 2014 May 30. PMID: 24878051

Kamrath C, Hartmann MF, Boettcher C, Wudy SA. Reduced activity of 11 β -hydroxylase accounts for elevated 17 α -hydroxyprogesterone in preterms. *J Pediatr*. 2014 Aug;165(2):280-4. doi: 10.1016/j.jpeds.2014.04.011. Epub 2014 May 23. PMID: 24862381

Kamrath C, Hartmann MF, Wudy SA. The balance of cortisol-cortisone interconversion is shifted towards cortisol in neonates with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *J Steroid Biochem Mol Biol*. 2014 Sep;143:386-91. doi: 10.1016/j.jsbmb.2014.05.008. Epub 2014 May 23. PMID: 24861266

Nadar R, Phadke N, Khatod K, Khadilkar V, Khadilkar AV. Clinical applicability of rapid detection of SRY and DYS14 genes in patients with disorders of sex development using an indigenously developed 5' exonuclease based assay. *J Pediatr Endocrinol Metab*. 2014 Sep;27(9-10):869-72. doi: 10.1515/jpem-2013-0416. PMID: 24854532

Eklioglu BS, Atabek ME, Akyurek N, Piskin MM, Kilinc M. Aromatase deficiency in an adolescent girl misdiagnosed as congenital adrenal hyperplasia in infancy and childhood. *J Pediatr Endocrinol Metab*. 2014 Jul;27(7-8):593-4. doi: 10.1515/jpem-2013-0204. PMID: 24825080

Oncul M, Sahmay S, Tuten A, Acikgoz AS, Gurleyen HC. May AMH levels

distinguish LOCAH from PCOS among hirsute women? *Eur J Obstet Gynecol Reprod Biol.* 2014 Jul;178:183-7. doi: 10.1016/j.ejogrb.2014.03.032. Epub 2014 Apr 12. PMID: 24792539

Auchus RJ, Buschur EO, Chang AY, Hammer GD, Ramm C, Madrigal D, Wang G, Gonzalez M, Xu XS, Smit JW, Jiao J, Yu MK. Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency. *J Clin Endocrinol Metab.* 2014 Aug;99(8):2763-70. doi: 10.1210/jc.2014-1258. Epub 2014 Apr 29. PMID: 24780050

Ma D, Ge H, Li X, Jiang T, Chen F, Zhang Y, Hu P, Chen S, Zhang J, Ji X, Xu X, Jiang H, Chen M, Wang W, Xu Z. Haplotype-based approach for noninvasive prenatal diagnosis of congenital adrenal hyperplasia by maternal plasma DNA sequencing. *Gene.* 2014 Jul 10;544(2):252-8. doi: 10.1016/j.gene.2014.04.055. Epub 2014 Apr 24. PMID: 24768736

Gonçalves EM, Sewaybricker LE, Baptista F, Silva AM, Carvalho WR, Santos AO, de Mello MP, Lemos-Marini SH, Guerra G Jr. Performance of phalangeal quantitative ultrasound parameters in the evaluation of reduced bone mineral density assessed by DX in patients with 21 hydroxylase deficiency. *Ultrasound Med Biol.* 2014 Jul;40(7):1414-9. doi: 10.1016/j.ultrasmedbio.2013.12.027. Epub 2014 Apr 13. PMID: 24726797

Honour JW. 17-Hydroxyprogesterone in children, adolescents and adults. *Ann Clin Biochem.* 2014 Jul;51(Pt 4):424-440. Epub 2014 Apr 7. Review. PMID: 24711560

Fernández-García Salazar R, Muñoz-Darias C, Haro-Mora JJ, Almaraz MC, Audí L, Martínez-Tudela J, Yahyaoui R, Esteva I. Woman with virilizing congenital adrenal hyperplasia and Leydig cell tumor of the ovary. *Gynecol Endocrinol.* 2014 Aug;30(8):549-52. doi: 10.3109/09513590.2014.907260. Epub 2014 Apr 7. PMID: 24702195

Rivas MP, Moreira LM, Santo LD, Marques AC, El-Hani CN, Toralles MB. New studies of second and fourth digit ratio as a morphogenetic trait in subjects with congenital adrenal hyperplasia. *Am J Hum Biol.* 2014 Jul-Aug;26(4):559-61. doi: 10.1002/ajhb.22545. Epub 2014 Mar 25. PMID: 24668932

Hindmarsh PC. The child with difficult to control Congenital Adrenal Hyperplasia: is there a place for continuous subcutaneous hydrocortisone therapy. *Clin Endocrinol (Oxf).* 2014 Jul;81(1):15-8. doi: 10.1111/cen.12453. Epub 2014 Apr 15. PMID: 24655023

Boyse KL, Gardner M, Marvicsin DJ, Sandberg DE "It was an overwhelming thing": parents' needs after infant diagnosis with congenital adrenal hyperplasia. *J Pediatr Nurs.* 2014 Sep-Oct;29(5):436-41. doi:

10.1016/j.pedn.2014.01.007. Epub 2014 Jan 15. PMID: 24491814

Mouritsen A, Johansen ML, Wohlfahrt-Veje C, Hagen CP, Tinggaard J, Mieritz MG, Tefre de Renzy-Martin K, Soeborg T, Fallentin E, Juul A, Main KM. Determination of adrenal volume by MRI in healthy children: associations with age, body size, pubertal stage and serum levels of adrenal androgens. *Clin Endocrinol (Oxf)*. 2014 Aug;81(2):183-9. doi: 10.1111/cen.12414. Epub 2014 Feb 15. PMID: 24455980

Jürgensen M, Lux A, Wien SB, Kleinemeier E, Hiort O, Thyen U. Health-related quality of life in children with disorders of sex development (DSD). *Eur J Pediatr*. 2014 Jul;173(7):893-903. doi: 10.1007/s00431-014-2264-z. Epub 2014 Jan 28. PMID: 24469231

Falhammar H. Non-functioning adrenal incidentalomas caused by 21-hydroxylase deficiency or carrier status? *Endocrine*. 2014 Sep;47(1):308-14. doi: 10.1007/s12020-013-0162-1. Epub 2014 Jan 23. PMID: 24452876

Quality of life, social situation, and sexual satisfaction, in adult males with congenital adrenal hyperplasia. Falhammar H, Nyström HF, Thorén M. *Endocrine*. 2014 Sep;47(1):299-307. doi: 10.1007/s12020-013-0161-2. Epub 2014 Jan 10. PMID: 24408051

PCOS-Adolescence

El-Sharkawy AA, Abdelmotaleb GS, Aly MK, Kabel AM. Effect of metformin on sleep disorders in adolescent girls with polycystic ovarian syndrome. *J Pediatr Adolesc Gynecol*. 2014 Dec;27(6):347-52. doi: 10.1016/j.jpag.2014.01.004. Epub 2014 Sep 23. PMID: 25256878

da Silva Bouzas IC, Cader SA, Leão L, Kuschnir MC, Braga C. Menstrual Cycle Alterations during Adolescence: Early Expression of Metabolic Syndrome and Polycystic Ovary Syndrome. *J Pediatr Adolesc Gynecol*. 2014 Dec;27(6):335-41. doi: 10.1016/j.jpag.2014.01.002. Epub 2014 Sep 23. PMID: 25256874

Pawelczak M, Rosenthal J, Milla S, Liu YH, Shah B. Evaluation of the Pro-inflammatory Cytokine Tumor Necrosis Factor- α in Adolescents with Polycystic Ovary Syndrome. *J Pediatr Adolesc Gynecol*. 2014 Dec;27(6):356-9. doi: 10.1016/j.jpag.2014.01.104. Epub 2014 Sep 23. PMID: 25256873

Youngster M, Ward VL, Blood EA, Barnewolt CE, Emans SJ, Divasta AD. Utility of ultrasound in the diagnosis of polycystic ovary syndrome in adolescents. *Fertil Steril*. 2014 Nov;102(5):1432-8. doi:

10.1016/j.fertnstert.2014.07.1241. Epub 2014 Sep 16. PMID: 25226858

Cinar N, Cetinozman F, Aksoy DY, Elcin G, Yildiz BO. Comparison of adrenocortical steroidogenesis in women with post-adolescent severe acne and polycystic ovary syndrome. *J Eur Acad Dermatol Venereol*. 2014 Aug 29. doi: 10.1111/jdv.12696. [Epub ahead of print] PMID: 25176476

Ganie MA, Hassan S, Nisar S, Shamas N, Rashid A, Ahmed I, Douhat S, Mudassar S, Jan VM, Rashid F. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS). *Gynecol Endocrinol*. 2014 Nov;30(11):781-4. doi: 10.3109/09513590.2014.924099. Epub 2014 Aug 19. PMID: 25137507

West S, Lashen H, Bloigu A, Franks S, Puukka K, Ruukonen A, Järvelin MR, Tapanainen JS, Morin-Papunen L. Irregular menstruation and hyperandrogenaemia in adolescence are associated with polycystic ovary syndrome and infertility in later life: Northern Finland Birth Cohort 1986 study. *Hum Reprod*. 2014 Oct 10;29(10):2339-51. doi: 10.1093/humrep/deu200. Epub 2014 Aug 1. PMID: 25085801

Pinola P, Morin-Papunen LC, Bloigu A, Puukka K, Ruukonen A, Järvelin MR, Franks S, Tapanainen JS, Lashen H. Anti-Müllerian hormone: correlation with testosterone and oligo- or amenorrhoea in female adolescence in a population-based cohort study. *Hum Reprod*. 2014 Oct 10;29(10):2317-25. doi: 10.1093/humrep/deu182. Epub 2014 Jul 23. PMID: 25056088

Cengiz H, Ekin M, Dagdeviren H, Yildiz Ş, Kaya C, Kanawati A. Comparison of serum anti-Müllerian hormone levels in normal weight and overweight-obese adolescent patients with polycystic ovary syndrome. *Eur J Obstet Gynecol Reprod Biol*. 2014 Sep;180:46-50. doi: 10.1016/j.ejogrb.2014.06.018. Epub 2014 Jun 28. PMID: 25036408

Torchen LC, Fogel NR, Brickman WJ, Papanicolaou R, Dunaif A. Persistent apparent pancreatic β -cell defects in premenarchal PCOS relatives. *J Clin Endocrinol Metab*. 2014 Oct;99(10):3855-62. doi: 10.1210/jc.2014-1474. Epub 2014 Jul 16. PMID: 25029420

Cankaya S, Demir B, Aksakal SE, Dilbaz B, Demirtas C, Goktolga U. Insulin resistance and its relationship with high molecular weight adiponectin in adolescents with polycystic ovary syndrome and a maternal history of polycystic ovary syndrome. *Fertil Steril*. 2014 Sep;102(3):826-30. doi: 10.1016/j.fertnstert.2014.05.032. Epub 2014 Jun 25. PMID: 24973036

Mani H, Potdar N, Gleeson H. How to manage an adolescent girl presenting

with features of polycystic ovary syndrome (PCOS); an exemplar for adolescent health care in endocrinology. *Clin Endocrinol (Oxf)*. 2014 Nov;81(5):652-6. doi: 10.1111/cen.12501. Epub 2014 Jul 7. PMID: 2482698

Kahraman K, Sükür YE, Atabekoğlu CS, Ateş C, Taşkın S, Cetinkaya SE, Tolunay HE, Ozmen B, Sönmezer M, Berker B. Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial. *Arch Gynecol Obstet*. 2014 Aug;290(2):321-8. doi: 10.1007/s00404-014-3217-5. Epub 2014 Mar 28. PMID: 24676694

Gooding HC, Milliren C, St Paul M, Mansfield MJ, DiVasta A. Diagnosing dysglycemia in adolescents with polycystic ovary syndrome. *J Adolesc Health*. 2014 Jul;55(1):79-84. doi: 10.1016/j.jadohealth.2013.12.020. Epub 2014 Feb 20. PMID: 24560306

PCOS-Dermatology

Hagag P, Steinschneider M, Weiss M. Role of the combination spironolactone-norgestimate-estrogen in Hirsute women with polycystic ovary syndrome. *J Reprod Med*. 2014 Sep-Oct;59(9-10):455-63. PMID: 25330687

PCOS-Endocrine Disruptors

Patisaul HB¹, Mabrey N², Adewale HB², Sullivan AW². Soy but not bisphenol A (BPA) induces hallmarks of polycystic ovary syndrome (PCOS) and related metabolic co-morbidities in rats. *Reprod Toxicol*. 2014 Sep 19;49C:209-218. doi: 10.1016/j.reprotox.2014.09.003. [Epub ahead of print] PMID: 25242113

PCOS-Animal models

Várbíró S, Sára L, Antal P, Monori-Kiss A, Tóké AM, Monos E, Benkő R, Csibi N, Szekeres M, Tarszabo R, Novak A, Paragi P, Nádasy GL. Lower-limb veins are thicker and vascular reactivity is decreased in a rat PCOS model: concomitant vitamin D3 treatment partially prevents these changes. *Am J Physiol Heart Circ Physiol*. 2014 Sep 15;307(6):H848-57. doi: 10.1152/ajpheart.01024.2013. Epub 2014 Jul 11. PMID: 25015958

Huang Y, Li W, Wang CC, Wu X, Zheng J. Cryptotanshinone reverses ovarian insulin resistance in mice through activation of insulin signaling and the regulation of glucose transporters and hormone synthesizing enzymes. *Fertil Steril*. 2014 Aug;102(2):589-596.e4. doi: 10.1016/j.fertnstert.2014.05.012. Epub 2014 Jun 25. PMID: 24973798

Caldwell AS, Middleton LJ, Jimenez M, Desai R, McMahon AC, Allan CM, Handelsman DJ, Walters KA. Characterization of reproductive, metabolic, and

endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models. *Endocrinology*. 2014 Aug;155(8):3146-59. doi: 10.1210/en.2014-1196. Epub 2014 May 30. PMID: 24877633

Yan X, Yuan C, Zhao N, Cui Y, Liu J. Prenatal androgen excess enhances stimulation of the GNRH pulse in pubertal female rats. *J Endocrinol*. 2014 Jul;222(1):73-85. doi: 10.1530/JOE-14-0021. Epub 2014 May 14. PMID: 24829217

PCOS-General Health

Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, Kelestimur F, Macut D, Micic D, Pasquali R, Pfeifer M, Pignatelli D, Pugeat M, Yildiz B; ESE PCOS Special Interest Group. European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group's Questionnaire. *Eur J Endocrinol*. 2014 Oct;171(4):489-98. doi: 10.1530/EJE-14-0252. Epub 2014 Jul 21. PMID: 25049203

Cheema BS, Vizza L, Swaraj S. Progressive resistance training in polycystic ovary syndrome: can pumping iron improve clinical outcomes? *Sports Med*. 2014 Sep;44(9):1197-207. doi: 10.1007/s40279-014-0206-6. PMID: 24872311

Mani H, Potdar N, Gleeson H. How to manage an adolescent girl presenting with features of polycystic ovary syndrome (PCOS); an exemplar for adolescent health care in endocrinology. *Clin Endocrinol (Oxf)*. 2014 Nov;81(5):652-6. doi: 10.1111/cen.12501. Epub 2014 Jul 7. PMID: 24826983

Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. *Hum Reprod Update*. 2014 Sep-Oct;20(5):748-58. doi: 10.1093/humupd/dmu012. Epub 2014 Mar 30. Review. PMID: 24688118

PCOS – Genetics

Cui Y, Zhao S, Zhao H, Lv Y, Yu M, Wang Y, Chen ZJ. Mutational analysis of TOX3 in Chinese Han women with polycystic ovary syndrome. *Reprod Biomed Online*. 2014 Sep 27. pii: S1472-6483(14)00473-8. doi: 10.1016/j.rbmo.2014.08.004. [Epub ahead of print] PMID: 25311971.

Eriksen MB, Glintborg D, Nielsen MF, Jakobsen MA, Brusgaard K, Tan Q, Gaster M. Testosterone treatment increases androgen receptor and aromatase gene expression in myotubes from patients with PCOS and controls, but does not induce insulin resistance. *Biochem Biophys Res Commun*. 2014 Sep 5;451(4):622-6. doi: 10.1016/j.bbrc.2014.08.033. Epub 2014 Aug 14. PMID: 25130462.

Goodarzi MO, Carmina E, Azziz R. DHEA, DHEAS and PCOS. *J Steroid Biochem Mol Biol*. 2014 Jul 5. pii: S0960-0760(14)00117-4. doi: 10.1016/j.jsbmb.2014.06.003. [Epub ahead of print] Review. PMID: 25008465.

Grolmusz VK, Acs OD, Feldman-Kovács K, Szappanos Á, Stenczer B, Fekete T, Szendei G, Reismann P, Rácz K, Patócs A. Genetic variants of the HSD11B1 gene promoter may be protective against polycystic ovary syndrome. *Mol Biol Rep*. 2014 Sep;41(9):5961-9. doi: 10.1007/s11033-014-3473-2. Epub 2014 Jun 27. PMID: 24969481.

Jędrzejuk D, Laczmański L, Kuliczowska J, Lenarcik A, Trzmiel-Bira A, Hirnle L, Dorobisz U, Milewicz A, Lwow F, Urbanowych A, Słoka N. Selected CNR1 polymorphisms and hyperandrogenemia as well as fat mass and fat distribution in women with polycystic ovary syndrome. *Gynecol Endocrinol*. 2014 Aug 5:1-4. [Epub ahead of print] PMID: 25093427.

Kuhtz J, Romero S, De Vos M, Smits J, Haaf T, Anckaert E. Human in vitro oocyte maturation is not associated with increased imprinting error rates at LIT1, SNRPN, PEG3 and GTL2. *Hum Reprod*. 2014 Sep;29(9):1995-2005. doi: 10.1093/humrep/deu155. Epub 2014 Jun 24. PMID: 24963167.

Mannerås-Holm L, Benrick A, Stener-Victorin E. Gene expression in subcutaneous adipose tissue differs in women with polycystic ovary syndrome and controls matched pair-wise for age, body weight, and body mass index. *Adipocyte*. 2014 Jul 1;3(3):190-6. doi: 10.4161/adip.28731. Epub 2014 Apr 4. PMID: 25068085.

Reddy KR, Deepika ML, Supriya K, Latha KP, Rao SS, Rani VU, Jahan P. CYP11A1 microsatellite (tttta)_n polymorphism in PCOS women from South India. *J Assist Reprod Genet*. 2014 Jul;31(7):857-63. doi: 10.1007/s10815-014-0236-x. Epub 2014 May 4. PMID: 24793009.

Scholten M, Vilser C, Weise A, Baniahmad A. Atypical Polycystic Ovary Syndrome - A Genetic Analysis. *Exp Clin Endocrinol Diabetes*. 2014 Aug 22. [Epub ahead of print] PMID: 25148265.

Sørensen AE, Wissing ML, Salö S, Englund AL, Dalgaard LT. MicroRNAs Related to Polycystic Ovary Syndrome (PCOS). *Genes (Basel)*. 2014 Aug 25;5(3):684-708. doi: 10.3390/genes5030684. Review. PMID: 25158044.

Thathapudi S, Kodati V, Erukkambattu J, Katragadda A, Addepally U, Hasan Q. Tumor necrosis factor-alpha and polycystic ovarian syndrome: a clinical,

biochemical, and molecular genetic study. *Genet Test Mol Biomarkers*. 2014 Sep;18(9):605-9. doi: 10.1089/gtmb.2014.0151. Epub 2014 Aug 1. PMID: 25083576.

Wang XX, Wei JZ, Jiao J, Jiang SY, Yu DH, Li D. Genome-wide DNA methylation and gene expression patterns provide insight into polycystic ovary syndrome development. *Oncotarget*. 2014 Aug 30;5(16):6603-10. PMID: 25051372.

Xu N, Chua AK, Jiang H, Liu NA, Goodarzi MO. Early embryonic androgen exposure induces transgenerational epigenetic and metabolic changes. *Mol Endocrinol*. 2014 Aug;28(8):1329-36. doi: 10.1210/me.2014-1042. Epub 2014 Jul 3. PMID: 24992182.

Yu M, Feng R, Sun X, Wang H, Wang H, Sang Q, Jin L, He L, Wang L. Polymorphisms of pentanucleotide repeats (tttta)_n in the promoter of CYP11A1 and their relationships to polycystic ovary syndrome (PCOS) risk: a meta-analysis. *Mol Biol Rep*. 2014 Jul;41(7):4435-45. doi: 10.1007/s11033-014-3314-3. Epub 2014 Mar 9. PMID: 24610422.

PCOS - Immunological Considerations

Cloix L, Reverchon M, Cornuau M, Froment P, Ramé C, Costa C, Froment G, Lecomte P, Chen W, Royère D, Guerif F, Dupont J. Expression and regulation of INTELECTIN1 in human granulosa-lutein cells: role in IGF-1-induced steroidogenesis through NAMPT. *Biol Reprod*. 2014 Aug;91(2):50. doi: 10.1095/biolreprod.114.120410. Epub 2014 Jun 18. PMID: 24943040.

PCOS - After the Menopause

Livadas S, Kollias A, Panidis D, Diamanti-Kandarakis E. Diverse impacts of aging on insulin resistance in lean and obese women with polycystic ovary syndrome: evidence from 1345 women with the syndrome. *Eur J Endocrinol*. 2014 Sep;171(3):301-9. doi: 10.1530/EJE-13-1007. PMID: 25053727.

PCOS - Metabolic Dysfunction/Cardiovascular Disease/Inflammation

Akcalı A, Bostancı N, Özçaka Ö, Öztürk-Ceyhan B, Gümüş P, Buduneli N, Belibasakis GN. *PLoS One*. Association between polycystic ovary syndrome, oral microbiota and systemic antibody responses. 2014 Sep 18;9(9):e108074. doi: 10.1371/journal.pone.0108074. eCollection 2014. PMID: 25232962.

Almario RU, Karakas SE. Roles of Circulating WNT-Signaling Proteins and WNT-Inhibitors in Human Adiposity, Insulin Resistance, Insulin Secretion, and Inflammation. *Horm Metab Res*. 2014 Aug 4. [Epub ahead of print] PMID: 25089371.

Androulakis II, Kandaraki E, Christakou C, Karachalios A, Marinakis E, Paterakis T, Diamanti-Kandarakis E. Visceral adiposity index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome. *Clin Endocrinol (Oxf)*. 2014 Sep;81(3):426-31. doi: 10.1111/cen.12447. Epub 2014 Apr 15. PMID: 24601936.

Bhagavath B, Vitek W, Queenan J, Hoeger K. Metformin and other insulin sensitizers in polycystic ovary syndrome. *Semin Reprod Med*. 2014 Jul;32(4):323-30. doi: 10.1055/s-0034-1375186. Epub 2014 Jun 11. PMID: 24919033.

Chaabouni K, Lahyani A, Turki M, Messedi M, Louati D, Jamoussi K, Ayedi F. Metabolic and inflammatory profiles in polycystic ovary syndrome associated to weight excess. *Ann Biol Clin (Paris)*. 2014 Aug 1;72(4):500-502. PMID: 25119811.

Chatterjee B, Suri J, Suri JC, Mittal P, Adhikari T. Impact of sleep-disordered breathing on metabolic dysfunctions in patients with polycystic ovary syndrome. *Sleep Med*. 2014 Sep 16. pii: S1389-9457(14)00345-1. doi: 10.1016/j.sleep.2014.06.023. [Epub ahead of print] PMID: 25311833.

Cicero AF, Reggi A, Parini A, Morbini M, Rosticci M, Grandi E, Borghi C. Berberine and monacolin effects on the cardiovascular risk profile of women with oestrogen-induced hypercholesterolemia. *High Blood Press Cardiovasc Prev*. 2014 Sep;21(3):221-6. doi: 10.1007/s40292-014-0052-5. Epub 2014 Apr 12. PMID: 24728953.

Daan NM, Louwers YV, Koster MP, Eijkemans MJ, de Rijke YB, Lentjes EW, Fauser BC, Laven JS. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? *Fertil Steril*. 2014 Sep 16. pii: S0015-0282(14)02027-5. doi: 10.1016/j.fertnstert.2014.08.001. [Epub ahead of print] PMID: 25239303.

de Ávila MA, Borges LP, Paez MS, Bruno RV, Nardi AE, de Pessôa AC, Palmeira Ede S. [Acanthosis nigricans: metabolic interrelations inherent to the polycystic ovary syndrome]. *Rev Bras Ginecol Obstet*. 2014 Sep;36(9):410-5. Portuguese. PMID: 25272362.

de Medeiros SF, Yamamoto MM, Bueno HB, Belizario D, Barbosa JS. Prevalence of elevated glycated hemoglobin concentrations in the polycystic ovary syndrome: anthropometrical and metabolic relationship in amazonian women. *J Clin Med Res*. 2014 Aug;6(4):278-86. doi:10.14740/jocmr1829w. Epub 2014 May 22. PMID: 24883154.

Desai V, Prasad NR, Manohar SM, Sachan A, Narasimha SR, Bitla AR. Oxidative stress in non-obese women with polycystic ovarian syndrome. *J Clin Diagn Res*. 2014 Jul;8(7):CC01-3. doi: 10.7860/JCDR/2014/8125.4530. Epub 2014 Jul 20. PMID: 25177558.

Doğanay M, Ozyer SS, Var T, Tonguc E, Gun Eryilmaz O, Ozer I, Guzel AI. Associations between adipocyte fatty acid-binding protein and clinical parameters in polycystic ovary syndrome. *Arch Gynecol Obstet*. 2014 Aug 20. [Epub ahead of print] PMID: 25138125.

Ezeh U, Pall M, Mathur R, Azziz R. Association of fat to lean mass ratio with metabolic dysfunction in women with polycystic ovary syndrome. *Hum Reprod*. 2014 Jul;29(7):1508-17. Epub 2014 May 9. PMID: 24813197.

Gambineri A, Fanelli F, Tomassoni F, Munarini A, Pagotto U, Andrew R, Walker BR, Pasquali R. Tissue-specific dysregulation of 11 β -hydroxysteroid dehydrogenase type 1 in overweight/obese women with polycystic ovary syndrome compared with weight-matched controls. *Eur J Endocrinol*. 2014 Jul;171(1):47-57. doi: 10.1530/EJE-13-1030. Epub 2014 Apr 17. PMID: 24743397.

Gidwani S, Phelan N, McGill J, McGowan A, O'Connor A, Young IS, Gibney J, McEneny J. Polycystic ovary syndrome influences the level of serum amyloid A and activity of phospholipid transfer protein in HDL₂ and HDL₃. *Hum Reprod*. 2014 Jul;29(7):1518-25. Epub 2014 May 19. PMID: 24842896.

Glintborg D, Altinok M, Mumm H, Buch K, Ravn P, Andersen M. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome. *Hum Reprod*. 2014 Aug;29(8):1773-9. doi: 10.1093/humrep/deu133. Epub 2014 Jun 4. PMID: 24903198.

González F, Sreekumaran Nair K, Basal E, Bearson DM, Schimke JM, Blair HE. Induction of Hyperandrogenism in Lean Reproductive-Age Women Stimulates Proatherogenic Inflammation. *Horm Metab Res*. 2014 Sep 17. [Epub ahead of print] PMID: 25230323.

Helvacı N, Yildiz BO. Oral contraceptives in polycystic ovary syndrome. *Minerva Endocrinol*. 2014 Sep;39(3):175-87. Epub 2014 Jul 8. PMID: 25003228.

Højlund K. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance. *Dan Med J*. 2014 Jul;61(7):B4890. PMID: 25123125.

Hsu CL, Hsiu H, Hsu WC, Chen CY. Characteristics of harmonic indexes of the arterial blood pressure waveform in polycystic ovary syndrome. *Blood Press Monit*. 2014 Aug;19(4):226-32. doi: 10.1097/MBP.0000000000000044. PMID: 24743683.

Keskin Kurt R, Okyay AG, Hakverdi AU, Gungoren A, Dolapcioglu KS, Karateke A, Dogan MO. The effect of obesity on inflammatory markers in patients with PCOS: a BMI-matched case-control study. *Arch Gynecol Obstet*. 2014 Aug;290(2):315-9. doi: 10.1007/s00404-014-3199-3. Epub 2014 Mar 19. PMID: 24643802.

Kim JW, Kang KM, Yoon TK, Shim SH, Lee WS. Study of circulating hepcidin in association with iron excess, metabolic syndrome, and BMP-6 expression in granulosa cells in women with polycystic ovary syndrome. *Fertil Steril*. 2014 Aug;102(2):548-554.e2. doi: 10.1016/j.fertnstert.2014.04.031. Epub 2014 May 27. PMID: 24875397.

Kobaly K, Vellanki P, Sisk RK, Armstrong L, Lee JY, Lee J, Hayes MG, Urbanek M, Legro RS, Dunaif A. Parent-of-origin effects on glucose homeostasis in polycystic ovary syndrome. *J Clin Endocrinol Metab*. 2014 Aug;99(8):2961-6. doi: 10.1210/jc.2013-4338. Epub 2014 May 30. PMID: 24878041.

Königer A, Edimiris P, Koch L, Enekwe A, Lamina C, Kasimir-Bauer S, Kimmig R, Dieplinger H. Serum concentrations of afamin are elevated in patients with polycystic ovary syndrome. *Endocr Connect*. 2014 Sep;3(3):120-6. doi: 10.1530/EC-14-0053. Epub 2014 Jun 13. PMID: 24928911.

Leão LM, Maranhão PA, Oliveira V, Villela NR, Bordallo MA, Borges MA, Bouskela E, Kraemer-Aguiar LG. Non-Obese Young Women with Polycystic Ovary Syndrome have Nutritive Microvascular Dysfunction: A Pilot Study. *Endocr Pract*. 2014 Aug 6:1-24. [Epub ahead of print] PMID: 25100380.

Mendoza N, Simoncini T, Genazzani AD. Hormonal contraceptive choice for women with PCOS: a systematic review of randomized trials and observational studies. *Gynecol Endocrinol*. 2014 Sep 25:1-11. [Epub ahead of print] PMID: 25254621.

Morciano A, Romani F, Sagnella F, Scarinci E, Palla C, Moro F, Tropea A, Policola C, Della Casa S, Guido M, Lanzone A, Apa R. Assessment of insulin resistance in lean women with polycystic ovary syndrome. *Fertil Steril*. 2014 Jul;102(1):250-256.e3. doi: 10.1016/j.fertnstert.2014.04.004. Epub 2014 May 10. PMID: 24825420.

Palomba S, Falbo A, Chiossi G, Orio F, Tolino A, Colao A, La Sala GB, Zullo F. Low-grade chronic inflammation in pregnant women with polycystic ovary syndrome: a prospective controlled clinical study. *J Clin Endocrinol Metab*. 2014 Aug;99(8):2942-51. doi: 10.1210/jc.2014-1214. Epub 2014 May 29. PMID: 24873996.

Pawelczak M, Rosenthal J, Milla S, Liu YH, Shah B. Evaluation of the Pro-inflammatory Cytokine Tumor Necrosis Factor- α in Adolescents with Polycystic Ovary Syndrome. *J Pediatr Adolesc Gynecol*. 2014 Sep 22. pii: S1083-3188(14)00109-0. doi: 10.1016/j.jpag.2014.01.104. [Epub ahead of print] PMID: 25256873.

Pei YJ, Wang AM, Zhao Y, Yan L, Li M, White RE, Han GC. Studies of cardiovascular risk factors in polycystic ovary syndrome patients combined with subclinical hypothyroidism. *Gynecol Endocrinol*. 2014 Aug;30(8):553-6. doi: 10.3109/09513590.2013.829443. Epub 2014 Jun 2. PMID: 24884959.

Peigné M, Dewailly D. Long term complications of polycystic ovary syndrome (PCOS). *Ann Endocrinol (Paris)*. 2014 Sep;75(4):194-9. doi: 10.1016/j.ando.2014.07.111. Epub 2014 Aug 23. PMID: 25156132.

Ramezani Tehrani F, Minooe S, Azizi F. Comparison of various adiposity indexes in women with polycystic ovary syndrome and normo-ovulatory non-hirsute women: a population-based study. *Eur J Endocrinol*. 2014 Aug;171(2):199-207. doi: 10.1530/EJE-14-0094. Epub 2014 May 9. PMID: 24816947.

Rees E, Coulson R, Dunstan F, Evans WD, Blundell HL, Luzio SD, Dunseath G, Halcox JP, Fraser AG, Rees DA. Central arterial stiffness and diastolic dysfunction are associated with insulin resistance and abdominal obesity in young women but polycystic ovary syndrome does not confer additional risk. *Hum Reprod*. 2014 Sep;29(9):2041-9. doi: 10.1093/humrep/deu180. Epub 2014 Jul 17. PMID: 25035436.

Seeber B, Morandell E, Lunger F, Wildt L, Dieplinger H. Afamin serum concentrations are associated with insulin resistance and metabolic syndrome in polycystic ovary syndrome. *Reprod Biol Endocrinol*. 2014 Sep 10;12:88. doi: 10.1186/1477-7827-12-88. PMID: 25208973.

Snyder ML, Shields KJ, Korytkowski MT, Sutton-Tyrrell K, Talbott EO. Complement protein C3 and coronary artery calcium in middle-aged women with polycystic ovary syndrome and controls. *Gynecol Endocrinol*. 2014 Jul;30(7):511-5. doi: 10.3109/09513590.2014.895985. Epub 2014 Mar 5. PMID: 24592986.

Stuckey BG, Opie N, Cussons AJ, Watts GF, Burke V. Clustering of metabolic and cardiovascular risk factors in the polycystic ovary syndrome: a principal component analysis. *Metabolism*. 2014 Aug;63(8):1071-7. doi: 10.1016/j.metabol.2014.05.004. Epub 2014 May 10. PMID: 24929892.

Takahashi T, Igarashi H, Hara S, Amita M, Matsuo K, Hasegawa A, Kurachi H. Brachial-to-ankle pulse wave velocity as an independent prognostic factor for ovulatory response to clomiphene citrate in women with polycystic ovary syndrome. *J Ovarian Res*. 2014 Jul 10;7:74. doi: 10.1186/1757-2215-7-74. eCollection 2014. PMID: 25024746.

Tsouma I, Kouskouni E, Demeridou S, Boutsikou M, Hassiakos D, Chasiakou A, Hassiakou S, Baka S. Correlation of visfatin levels and lipoprotein lipid profiles in women with polycystic ovary syndrome undergoing ovarian stimulation. *Gynecol Endocrinol*. 2014 Jul;30(7):516-9. doi: 10.3109/09513590.2014.896896. Epub 2014 Feb 27. PMID: 24576225.

Tsouma I, Kouskouni E, Demeridou S, Boutsikou M, Hassiakos D, Chasiakou A, Hassiakou S, Gennimata V, Baka S. Lipid lipoprotein profile alterations in Greek infertile women with polycystic ovaries: influence of adipocytokines levels. *In Vivo*. 2014 Sep-Oct;28(5):935-9. PMID: 25189910.

Uçar A, Yackobovitch-Gavan M, Erol OB, Yekeler E, Saka N, Baç F, Poyrazoğlu S, Bundak R, Darendeliler F. Associations of size at birth and postnatal catch-up growth status with clinical and biomedical characteristics in prepubertal girls with precocious adrenarche: preliminary results. *J Clin Endocrinol Metab.* 2014 Aug;99(8):2878-86. doi: 10.1210/jc.2013-3144. Epub 2014 Apr 7. PMID: 24708094.

Unfer V, Porcaro G. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome. *Expert Rev Clin Pharmacol.* 2014 Sep;7(5):623-31. doi: 10.1586/17512433.2014.925795. Epub 2014 Jun 5. PMID: 24898153.

Xu X, Du C, Zheng Q, Peng L, Sun Y. Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review. *BMC Womens Health.* 2014 Aug 5;14:93. doi: 10.1186/1472-6874-14-93. PMID: 25096410.

PCOS - Neuroendocrine Dysfunction

Haider S, Mannan N, Khan A, Qureshi MA. Influence of anthropometric measurements on abnormal gonadotropin secretion in women with polycystic ovary syndrome. *J Coll Physicians Surg Pak.* 2014 Jul;24(7):463-6. doi: 10.2014/JCPSP.463466.

Lauritsen MP, Pinborg A, Loft A, Petersen JH, Mikkelsen AL, Bjerre MR, Nyboe Andersen A. Revised criteria for PCOS in WHO Group II anovulatory infertility - a revival of hypothalamic amenorrhoea? *Clin Endocrinol (Oxf).* 2014 Sep 26. doi: 10.1111/cen.12621. [Epub ahead of print] PMID: 25262871.

PCOS – Ovary

Bili AE, Dampala K, Iakovou I, Tsolakidis D, Giannakou A, Tarlatzis BC. The combination of ovarian volume and outline has better diagnostic accuracy than prostate-specific antigen (PSA) concentrations in women with polycystic ovarian syndrome (PCOs). *Eur J Obstet Gynecol Reprod Biol.* 2014 Aug;179:32-5. doi: 10.1016/j.ejogrb.2014.05.006. Epub 2014 May 20. PMID: 24965976.

Moazami Goudarzi Z, Fallahzadeh H, Aflatoonian A, Mirzaei M. Laparoscopic ovarian electrocautery versus gonadotropin therapy in infertile women with clomiphene citrate-resistant polycystic ovary syndrome: A systematic review and meta-analysis. *Iran J Reprod Med.* 2014 Aug;12(8):531-538. PMID: 25408702.

PCOS - Phenotypic Variation

de Medeiros SF, Barbosa JS, Yamamoto MM. Comparison of steroidogenic pathways among normoandrogenic and hyperandrogenic polycystic ovary

syndrome patients and normal cycling women. *J Obstet Gynaecol Res.* 2014 Sep 26. doi: 10.1111/jog.12524. [Epub ahead of print] PMID: 25256274.

Hosseinpanah F, Barzin M, Keihani S, Ramezani Tehrani F, Azizi F. Metabolic aspects of different phenotypes of polycystic ovary syndrome: Iranian PCOS Prevalence Study. *Clin Endocrinol (Oxf).* 2014 Jul;81(1):93-9. doi: 10.1111/cen.12406. Epub 2014 Jan 31. PMID: 24428207.

Palomba S, Falbo A, Chiossi G, Tolino A, Tucci L, La Sala GB, Zullo F. Early trophoblast invasion and placentation in women with different PCOS phenotypes. *Reprod Biomed Online.* 2014 Sep;29(3):370-81. doi: 10.1016/j.rbmo.2014.04.010. Epub 2014 May 14. PMID: 24928355.

Tal R, Seifer DB, Khamov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. *Am J Obstet Gynecol.* 2014 Jul;211(1):59.e1-8. doi: 10.1016/j.ajog.2014.02.026. Epub 2014 Mar 2. PMID: 24593938.

Tehrani FR, Rashidi H, Khomami MB, Tohidi M, Azizi F. The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran. *Reprod Biol Endocrinol.* 2014 Sep 16;12:89. doi: 10.1186/1477-7827-12-89. PMID: 25224635.

PCOS-Pregnancy Complications

Capula C, Chiefari E, Vero A, Foti DP, Brunetti A, Vero R. Prevalence and predictors of postpartum glucose intolerance in Italian women with gestational diabetes mellitus. *Diabetes Res Clin Pract.* 2014 Aug;105(2):223-30. doi: 10.1016/j.diabres.2014.05.008. Epub 2014 May 29. PMID: 24931701

Palomba S, Falbo A, Chiossi G, Orio F, Tolino A, Colao A, La Sala GB, Zullo F. Low-grade chronic inflammation in pregnant women with polycystic ovary syndrome: a prospective controlled clinical study. *J Clin Endocrinol Metab.* 2014 Aug;99(8):2942-51. doi: 10.1210/jc.2014-1214. Epub 2014 May 29. PMID: 24873996

Cassina M, Donà M, Di Gianantonio E, Litta P, Clementi M. First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis. *Hum Reprod Update.* 2014 Sep-Oct;20(5):656-69. doi: 10.1093/humupd/dmu022. Epub 2014 May 25. Review. PMID: 24861556

Pasquali R. Reproductive endocrinology: Maternal and fetal insulin levels at birth in women with PCOS. *Nat Rev Endocrinol*. 2014 Jul;10(7):382-4. doi: 10.1038/nrendo.2014.61. Epub 2014 May 6. PMID: 24798059

Tal R, Seifer DB, Kxanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. *Am J Obstet Gynecol*. 2014 Jul;211(1):59.e1-8. doi: 10.1016/j.ajog.2014.02.026. Epub 2014 Mar 2. PMID: 24593938

PCOS RCTs

Deveci CD, Demir B, Sengul O, Dilbaz B, Goktolga U. Clomiphene citrate 'stair-step' protocol vs. traditional protocol in patients with polycystic ovary syndrome: a randomized controlled trial. *Arch Gynecol Obstet*. 2014 Jul 31. [Epub ahead of print] PMID: 25078053

Glintborg D, Altinok ML, Mumm H, Hermann AP, Ravn P, Andersen M. Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. *J Clin Endocrinol Metab*. 2014 Jul;99(7):2584-91. doi: 10.1210/jc.2014-1135. Epub 2014 Apr 17. PMID: 24742124

PCOS Psychology

Naqvi SH, Moore A, Bevilacqua K, Lathief S, Williams J, Naqvi N, Pal L. Predictors of depression in women with polycystic ovary syndrome. *Arch Womens Ment Health*. 2014 Sep 11. [Epub ahead of print] PMID: 25209354

Sirmans SM, Parish RC, Blake S, Wang X. Epidemiology and comorbidities of polycystic ovary syndrome in an indigent population. *J Investig Med*. 2014 Aug;62(6):868-74. doi: 10.1097/01.JIM.0000446834.90599.5d. PMID: 24844662

Barry JA, Kuczmierczyk AR, Hardiman PJ. Reporting the rates of depression in polycystic ovary syndrome (PCOS). *J Sex Med*. 2014 Jul;11(7):1882-3. doi: 10.1111/jsm.12503. Epub 2014 Mar 17. PMID: 24636134

Lin AW, Lujan ME. Comparison of dietary intake and physical activity between women with and without polycystic ovary syndrome: a review. *Adv Nutr*. 2014 Sep;5(5):486-96. PMID: 25469380

PCOS Thyroid complications

Al-Saab R, Haddad S. Detection of thyroid autoimmunity markers in euthyroid women with polycystic ovary syndrome: a case-control study from syria. *Int J Endocrinol Metab.* 2014 Jul 1;12(3):e17954. doi: 10.5812/ijem.17954. eCollection 2014 Jul. PMID: 25237328

Novais JD, Benetti-Pinto CL, Garmes HM, Menezes Jales R, Juliato CR. Polycystic ovary syndrome and chronic autoimmune thyroiditis. *Gynecol Endocrinol.* 2014 Sep 11:1-4. [Epub ahead of print] PMID: 25211537

Enzevaei A, Salehpour S, Tohidi M, Saharkhiz N. Subclinical hypothyroidism and insulin resistance in polycystic ovary syndrome: is there a relationship? *Iran J Reprod Med.* 2014 Jul;12(7):481-6. PMID: 25114670

Pei YJ, Wang AM, Zhao Y, Yan L, Li M, White RE, Han GC. Studies of cardiovascular risk factors in polycystic ovary syndrome patients combined with subclinical hypothyroidism. *Gynecol Endocrinol.* 2014 Aug;30(8):553-6. doi: 10.3109/09513590.2013.829443. Epub 2014 Jun 2. PMID: 24884959

Muscogiuri G, Mitri J, Mathieu C, Badenhop K, Tamer G, Orio F, Mezza T, Vieth R, Colao A, Pittas A. Mechanisms in endocrinology: vitamin D as a potential contributor in endocrine health and disease. *Eur J Endocrinol.* 2014 Sep;171(3):R101-10. doi: 10.1530/EJE-14-0158. Epub 2014 May 28. Review. PMID: 24872497

PCOS Uterus

Ito-Yamaguchi A, Suganuma R, Kumagami A, Hashimoto S, Yoshida-Komiya H, Fujimori K. Effects of metformin on endocrine, metabolic milieu and endometrial expression of androgen receptor in patients with polycystic ovary syndrome. *Gynecol Endocrinol.* 2014 Sep 19:1-4. [Epub ahead of print] PMID: 25237893

Saleh HA, Shawky Moiety FM. Polycystic ovarian syndrome and congenital uterine anomalies: the hidden common player. *Arch Gynecol Obstet.* 2014 Aug;290(2):355-60. doi: 10.1007/s00404-014-3193-9. Epub 2014 Mar 11. PMID: 24615567

Yu J, Ma Y, Wu Z, Li Y, Tang L, Li Y, Deng B. Endometrial preparation protocol of the frozen-thawed embryo transfer in patients with polycystic ovary syndrome. *Arch Gynecol Obstet.* 2014 Jul 31. [Epub ahead of print] PMID: 25091221

Plaza-Parrochia F, Bacallao K, Poblete C, Gabler F, Carvajal R, Romero C, Valladares L, Vega M. The role of androst-5-ene-3 β ,17 β -diol (androstenediol) in cell proliferation in endometrium of women with polycystic ovary syndrome. *Steroids*. 2014 Nov;89:11-9.

Ujvari U, Hulchiy M, Calaby A, Nybacka Å, Byström B, Hirschberg AL. Lifestyle intervention up-regulates gene and protein levels of molecules involved in insulin signaling in the endometrium of overweight/obese women with polycystic ovary syndrome. *Hum Reprod*. 2014 Jul;29(7):1526-35. Epub 2014 May 19. PMID: 24842895

Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. *Hum Reprod Update*. 2014 Sep-Oct;20(5):748-58. doi: 10.1093/humupd/dmu012. Epub 2014 Mar 30. Review. PMID: 24688118

PREMATURE ADRENARCHE

Mäntyselkä A, Jääskeläinen J, Lindi V, Viitasalo A, Tompuri T, Voutilainen R, Lakka TA. The presentation of adrenarche is sexually dimorphic and modified by body adiposity. *J Clin Endocrinol Metab*. 2014 Oct;99(10):3889-94. doi: 10.1210/jc.2014-2049. Epub 2014 Jul 16. PMID: 25029425

Miller WL, Tee MK. The post-translational regulation of 17,20 lyase activity. *Mol Cell Endocrinol*. 2014 Sep 16. pii: S0303-7207(14)00288-3. doi: 10.1016/j.mce.2014.09.010. [Epub ahead of print] Review. PMID: 25224484